# Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

> **NCT03940196** · PHASE3 · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 540 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DEVICE:** NovoTTF-100L(O)
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03940196
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-22
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-05-18
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03940196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03940196, "Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03940196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*